Catalyst Dossier · compiled by CeliA 🧫

Kyverna Therapeutics, Inc. (KYTX)

Biological Products, (No Diagnostic Substances) · market cap $491M · as of 2026-07-07

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Kyverna Therapeutics (KYTX) is a clinical-stage cell therapy company focused on autoimmune diseases, with 129 employees and a ~$540M market cap at ~$8.89/share. Its lead program is KYV-101, an anti-CD19 CAR-T therapy being evaluated across Lupus Nephritis, Systemic Sclerosis, and Multiple Sclerosis, alongside a Phase 3 Lupus Nephritis trial and a Phase 3 Myasthenia Gravis program. The company's most acute near-term issue is a reported cash position of $32.2M with a runway of only ~2.3 months, creating severe financing risk ahead of multiple pending readouts.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
KYV-101 anti-CD19 CAR-T cell therapy	Phase 2	Lupus Nephritis
Standard lymphodepletion regimen	Phase 3	Lupus Nephritis
Anti-CD20 mAB	Phase 2	Multiple Sclerosis, Primary Progressive
Standard of Care Treatment	Phase 3	Myasthenia Gravis
KYV-101	Phase 3	Systemic Sclerosis

Price & technical context

3-month

-23.9%

6-month

+11.0%

12-month

+135.4%

52-wk range

$3.30–$11.25

vs 50-day MA

+1.6%

vs 200-day MA

-1.7%

Realized vol

100.1%

Max drawdown

-81.7%

Daily closes through 2026-08-14. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for KYTX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.